BEVERLY, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation announced today the presentation of positive Phase 2 clinical data demonstrating the safety of INO-1001 as well as the potential for INO-1001 as a preventative agent for cardiac reperfusion injury. The study was conducted in subjects with acute ST-elevated myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. The presentation was made in a poster session at the American College of Cardiology (ACC) 56th Annual Scientific Session in New Orleans, Louisiana. INO-1001 is an inhibitor of poly(ADP-Ribose) polymerase (PARP), a nuclear enzyme that directs the repair of damaged DNA via the activation and recruitment of DNA repair enzymes and is being studied as a treatment for certain acute cardiovascular conditions and cancer. Additionally, PARP inhibition shows promise in inflammatory disorders. PARP’s role in the inflammatory response may result from its ability to potentiate the activity of key inflammatory transcription factors (NF-kappaB and AP-1).
